68ga-fap-rgd
PeptideexperimentalImaging agent
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2022 (NCT05515783)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 68-gallium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06638034 | Early Phase 1 (Phase 1) | May 1, 2024 | Chinese Academy of Medical Sciences |
| NCT05543954 | Early Phase 1 (Phase 1) | Sep 3, 2022 | Chinese Academy of Medical Sciences |
| NCT05515783 | Phase 1/Phase 2 (Phase 2) | May 1, 2022 | Fujian Medical University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 2 | 1 | 2022 |
| Fujian Medical University | Academic/Hospital | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1